Marshall Wace LLP Takes Position in Quanterix Co. (NASDAQ:QTRX)

Marshall Wace LLP acquired a new stake in Quanterix Co. (NASDAQ:QTRXFree Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 25,800 shares of the company’s stock, valued at approximately $341,000. Marshall Wace LLP owned about 0.07% of Quanterix as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board bought a new position in Quanterix in the 2nd quarter valued at $140,000. Hsbc Holdings PLC raised its position in Quanterix by 34.7% in the 2nd quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock worth $164,000 after purchasing an additional 3,279 shares during the period. Comerica Bank raised its position in Quanterix by 44,205.6% in the 1st quarter. Comerica Bank now owns 7,975 shares of the company’s stock worth $188,000 after purchasing an additional 7,957 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in Quanterix by 11.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 14,261 shares of the company’s stock worth $188,000 after acquiring an additional 1,417 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new stake in Quanterix in the 2nd quarter worth $210,000. Hedge funds and other institutional investors own 86.48% of the company’s stock.

Insiders Place Their Bets

In other Quanterix news, Director David R. Walt purchased 47,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were bought at an average price of $13.29 per share, with a total value of $624,630.00. Following the completion of the purchase, the director now directly owns 1,487,342 shares in the company, valued at $19,766,775.18. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 6.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group cut their price target on shares of Quanterix from $35.00 to $24.00 and set a “buy” rating on the stock in a report on Tuesday, July 9th. TD Cowen dropped their price objective on shares of Quanterix from $17.00 to $15.00 and set a “hold” rating on the stock in a research note on Friday, August 9th. Finally, Scotiabank dropped their price objective on shares of Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a research note on Monday, August 12th.

Get Our Latest Stock Analysis on QTRX

Quanterix Stock Up 6.3 %

QTRX opened at $11.76 on Friday. Quanterix Co. has a twelve month low of $10.50 and a twelve month high of $29.70. The stock has a market capitalization of $451.35 million, a price-to-earnings ratio of -11.20 and a beta of 1.36. The firm has a 50 day moving average price of $12.64 and a 200-day moving average price of $15.01.

Quanterix (NASDAQ:QTRXGet Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Quanterix had a negative net margin of 30.71% and a negative return on equity of 11.52%. The business had revenue of $34.38 million for the quarter, compared to analysts’ expectations of $34.19 million. During the same period in the prior year, the company posted ($0.16) earnings per share. As a group, analysts expect that Quanterix Co. will post -0.88 earnings per share for the current year.

Quanterix Company Profile

(Free Report)

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

Featured Stories

Institutional Ownership by Quarter for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.